ANI Pharmaceuticals, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00182C1036
USD
82.74
0.62 (0.75%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About ANI Pharmaceuticals, Inc. stock-summary
stock-summary
ANI Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.
Company Coordinates stock-summary
Company Details
210 W Main St , BAUDETTE MN : 56623-2467
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 65 Schemes (36.42%)

Foreign Institutions

Held by 97 Foreign Institutions (12.58%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Patrick Walsh
Chairman of the Board
Mr. Nikhil Lalwani
President, Chief Executive Officer, Director
Mr. Robert Brown
Independent Director
Mr. Thomas Haughey
Independent Director
Dr. David Nash
Independent Director
Mr. Thomas Penn
Independent Director
Mr. Antonio Pera
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
211 Million
(Quarterly Results - Jun 2025)
Net Profit:
8 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2,074 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.97

stock-summary
Return on Equity

-1.36%

stock-summary
Price to Book

4.75